- Entitlement Offer Shortfall of approximately 26.4 million shares placed to existing institutional and sophisticated investors raising A$7.4 million - Concludes Recce’s A$15.8 million capital raising consisting of A$5.0 million private placement and 1-for-6 entitlement offer and shortfall placement to raise a further A$10.8 million - Funds raised under the capital raising will be used to support significant Phase 3 clinical trials for topical treatments in Indonesia and Australia, which will progress Recce through to commercialisation, and an Investigational New Drug Application to the US FDA - Pro-forma cash balance of A$16.0 million
June 5, 2025
· 1 min read
